Tactile Systems Technology

TCMD on Nasdaq. Tactile Systems Technology sells at-home medical devices for chronic diseases to patients. Market value $509m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Worth a closer look

Read what could go wrong

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
5.3%fair

For every $100 of what the whole company costs, it produced $5.34 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
12.4×fair

You pay 12.4 years of operating profit for the business. The average large US company costs around 18.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 78 of 100. Price score: 89 of 100. Our list needs 70 on quality and 60 on price.

$22.19 a share, 59% above its 1-year low

Over the past year the price has ranged from $14.00 to $37.77.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

0.0
0.0
0.0
0.0
0.0
0.0
2021202220232024202512 monthsto Jun '26

Spare cash swings from quarter to quarter here: $27 million in the past 12 months, $40 million in the year to December 2025.

Revenue
$208m$247m$274m$293m$330m
Operating margin
-0.8%-5.2%6.6%7.6%8.9%
Debt to equity
n/an/a0.09n/a0.00
Shares outstanding
0.02bn0.02bn0.02bn0.02bn0.02bn

Health checks

  • Free cash flow positive5 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)7 of 8 checks we could run
  • Profit backed by cash (accruals)Yes
  • Debt0.00× equity
  • Revenue growth, five yearsStrong, 12.0% a year
  • Buying back its own sharesNo, 12% more shares since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $86 million last quarter, up 9% on a year ago.
  • Profit: $8 million, up 142% on a year ago.
  • It keeps 10 cents of each $1 of sales as operating profit, up from 6 cents a year earlier.
  • Spare cash over the past 12 months: $27 million, down from $40 million.
  • 1% fewer shares than a year ago. Each share owns a bit more of the company.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$73m
December 2024$86m
March 2025$61m
June 2025$79m
September 2025$86m
December 2025$104m
March 2026$75m
June 2026$86m
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024$5m
December 2024$10m
March 2025-$3m
June 2025$3m
September 2025$8m
December 2025$11m
March 2026-$2m
June 2026$8m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
17 February 2026
Next quarterly (estimated, 10-Q)
9 November 2026

Who owns it

2 long-term investors we follow own it, up from 1 last quarter. 181 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

3 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 3 sold $2m, $148,260 of it under preset trading plans.

  • Dodd Sheri Louise
    Chief Executive Officer, Director
    Sold
    Date
    10 August 2026
    Shares
    10,978
    Price
    $29.44
    Value
    $323,243
  • Birkemeyer Elaine M.
    CHIEF FINANCIAL OFFICER
    Sold
    Date
    11 May 2026
    Shares
    4,631
    Price
    $24.49
    Value
    $113,413
  • Birkemeyer Elaine M.
    CHIEF FINANCIAL OFFICER
    Sold
    Date
    24 February 2026
    Shares
    7,701
    Price
    $28.94
    Value
    $222,867
  • Burns Kristie
    Sr. VP Mktg & Clinical Affairs
    Sold
    Date
    24 February 2026
    Shares
    6,246
    Price
    $28.94
    Value
    $180,759
  • Dodd Sheri Louise
    Chief Executive Officer, Director
    Sold
    Date
    24 February 2026
    Shares
    10,993
    Price
    $28.94
    Value
    $318,137
  • Birkemeyer Elaine M.
    CHIEF FINANCIAL OFFICER
    Sold
    Date
    23 February 2026
    Shares
    5,518
    Price
    $28.29
    Value
    $156,129
  • Burns Kristie
    Sr. VP Mktg & Clinical Affairs
    Sold
    Date
    23 February 2026
    Shares
    4,439
    Price
    $28.29
    Value
    $125,601
  • Dodd Sheri Louise
    Chief Executive Officer, Director
    Sold
    Date
    23 February 2026
    Shares
    15,240
    Price
    $28.29
    Value
    $431,207
  • Burns Kristie
    Sr. VP Mktg & Clinical Affairs
    Sold
    under a preset trading plan
    Date
    2 January 2026
    Shares
    5,139
    Price
    $28.85
    Value
    $148,260

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 17 Feb 2026, plus the 10-Q filed 10 Aug 2026 and 5 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

What changed in the risks this year

Companies must list what could hurt them each year. These are the parts that changed since last year’s report.

  • Failure to effectively implement technology initiatives or anticipate future technology needs or demands could adversely affect our business or financial results .

    Could happen
    We are also exposed to the risk that generative AI may produce incorrect outputs, release confidential information, reflect biases, infringe intellectual property, or otherwise cause harm. Their complexity makes it challenging to understand outputs and comply with documentation or explanation requirements. Any of these risks could expose us to liability or adverse legal or regulatory consequences and harm our business or financial results.
    Read more
  • Failure to effectively implement technology initiatives or anticipate future technology needs or demands could adversely affect our business or financial results .

    Could happen
    The use of AI developed by third parties introduces risks related to how the AI is developed, trained, and deployed, including unauthorized material in training data and limited visibility into risk mitigation steps.
  • Failure to effectively implement technology initiatives or anticipate future technology needs or demands could adversely affect our business or financial results .

    Could happen
    The medical device industry is highly competitive and subject to rapid change and technological advancements. Therefore, it is important to our business that we continue to evaluate technology to determine whether it may help us compete on a cost-effective basis. The cost of investing in, implementing and maintaining such technology is high, and there can be no assurance, given the fast pace of change and innovation, that our technology, either purchased or developed internally, will meet our needs, in a timely and cost-effective manner or at all. During the course of implementing new technology into our operations, we may experience system interruptions and failures. In addition, there can be no assurance that we will recognize, in a timely manner or at all, the benefits that we may expect as a result of our implementing new technology. If we are not able to anticipate and keep pace with existing and future technology needs, our business, financial results, or reputation could be negatively impacted.
    Read more
  • Changes in funding or disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, authorized or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could adversely impact our business.

    The ability of the FDA to review and provide marketing authorization new products or changes to existing products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA’s ability to hire and retain key personnel and accept the payment of user fees, federal government shutdowns, and other events that may otherwise affect the FDA’s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund R&D activities is subject to the political process, which is inherently fluid and unpredictable. Decreases in government funding of research and development, including any reductions in funding to the U.S. National Institutes of Health may impact our business, as could changes in government programs that provide funding to research institutions and companies, including changes in the amount of funds allocated to different areas of research or changes that have the effect of increasing the length of time of the funding process. Disruptions at the FDA and other agencies may also slow the time necessary for new products, or modifications to authorized products, to be reviewed and/or authorized by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could adversely affect our business .
    Read more
  • Failure to effectively implement technology initiatives or anticipate future technology needs or demands could adversely affect our business or financial results .

    Could happen
    Our industry continually experiences technological changes, with frequent introductions of new technology-driven products and services, including recent and rapid developments in artificial intelligence ("AI"). There are risks in effectively implementing and marketing new technology-driven products and services. Upgrades and integration may cause service interruptions, transaction errors, and delays, and could cause us to fail to comply with applicable laws. There can be no assurance that we will be able to successfully manage the risks associated with an increased dependency on technology. Failure to successfully keep pace with technological change affecting our industry could negatively affect our revenue and profitability.
    Read more

Read it in the annual report

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.